Crispr Therapeutics AG (CRSP)

Crispr Therapeutics AG (CRSP) Financial Statements


Crispr Therapeutics AG Financial Overview

Crispr Therapeutics AG's market cap is currently ―. The company's EPS TTM is $-1.971; its P/E ratio is -31.92; Crispr Therapeutics AG is scheduled to report earnings on April 30, 2024, and the estimated EPS forecast is $-1.45. See an overview of income statement, balance sheet, and cash flow financials.
Dec 23Sep 23Jun 23Mar 23Dec 22
Income Statement-
Total Revenue$ 201.21M-$ 70.00M$ 100.00M$ 6.00K
Gross Profit$ 201.21M-$ 70.00M$ 100.00M$ -6.82M
EBIT$ 89.58M$ -111.74M$ -76.82M$ -51.74M$ -131.54M
EBITDA$ 94.48M$ -106.81M$ -71.86M$ -46.69M$ -125.69M
Net Income Common Stockholders$ -131.15M$ -65.31M$ -77.74M$ -53.06M$ -110.58M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 1.69B$ 1.74B$ 1.77B$ 1.88B$ 1.82B
Total Assets$ 2.23B$ 2.09B$ 2.20B$ 2.24B$ 2.24B
Total Debt$ 238.63M$ 241.59M$ 245.18M$ 240.27M$ 244.02M
Net Debt$ -1.46B$ -1.50B$ -1.52B$ -1.64B$ -1.57B
Total Liabilities$ 346.77M$ 359.04M$ 380.99M$ 389.47M$ 367.58M
Stockholders Equity$ 1.88B$ 1.73B$ 1.82B$ 1.85B$ 1.88B
Cash Flow-
Free Cash Flow$ -96.81M$ -41.97M$ -136.80M$ 5.74M$ -119.52M
Operating Cash Flow$ -96.07M$ -39.86M$ -133.25M$ 8.80M$ -113.33M
Investing Cash Flow$ -81.45M$ 121.35M$ 216.92M$ 117.83M$ -175.53M
Financing Cash Flow$ 38.94M$ 1.56M$ 16.77M$ 5.40M$ 2.48M
Currency in USD

Crispr Therapeutics AG Earnings and Revenue History

Crispr Therapeutics AG Debt to Assets

Crispr Therapeutics AG Cash Flow

Crispr Therapeutics AG Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis